Biotech Acquisition Co
Definitive Agreement
Follow
Detailed Information
Information on this SPAC.
- IPO Size
- $200M
- Underwriters
- Focus
- Healthcare, Biotech, Technology, Software
- SEC Filings
- 1825413
- Public Embarc Page
- https://embarc.com/capital/spac/1825413/BIOT/biotech-acquisition-co
SPAC Leadership
Information on the SPAC leadership.
- Chief Executive Officer and Chairman of the BoardMichael Shleifer
- Chief Operating OfficerIvan Jarry
- Chief Investment OfficerAlbert Hummel
- Chief Financial Officer and TreasurerThomas Fratacci
- DirectorBruno Montanari
- DirectorPaul Bernard
- DirectorAaron Kim
- AdvisorTanguy Serra(Co-founder, Vivint Solar, Fmr COO, SolarCity)
- AdvisorMichael Tillman
- Chief Executive Officer and Chairman of the BoardDr. Michael Shleifer(Co-founder/MP, SPRIM)
- Chief Investment Officer and DirectorAlbert F. Hummel
Target Information
Information on the SPAC target for merger.
- Company
- Blade Therapeutics, Inc.
- Presentation
- Investor Presentation (SEC) on 2022-04-11
- Description
- Blade is "a biopharmaceutical company based in South San Francisco"which "expects to advance a differentiated pipeline of oral, small-molecule therapies with disease-modifying potential that includes a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases."